Clinical Microbiology and Infection

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

P.-Y. Lévy Clinical Microbiology and Infection

B. Schulz, K. Weber, C. Radecke, C. Scheer, M. Ruhnke

Rapid streptococcal testing for sore throat and antibiotic resistance

L. Boyanova Clinical Microbiology and Infection

Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non- neutropenic models of invasive candidiasis N.P. Wiederhold, L.K.

In vitro and in vivo role of heat shock protein 90 in Amphotericin B resistance of Aspergillus terreus G. Blum, B. Kainzner, K. Grif, H. Dietrich, B.

Gut bacterial microbiota and obesity

T. Schneider, J. Halter, D. Heim, J. Passweg, M. Stern, A. Tichelli, M

Approach to diagnosis of infective endocarditis

S. Wagenpfeil, A. Neiss, K. Banz, P. Wutzler

Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications T.-L. Liao, Y.-M.

Migrant health—a cause for concern?

Clinical characteristics of Haemophilus influenzae meningitis in Denmark in the post- vaccination era T.I. Pedersen, M. Howitz, C. Østergaard Clinical.

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

J.-P. Van geertruyden Clinical Microbiology and Infection

R. Cantón Clinical Microbiology and Infection

Rapid streptococcal testing for sore throat and antibiotic resistance

Louis Pasteur, from crystals of life to vaccination

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

Chlamydia trachomatis infections in heterosexuals attending sexually transmitted disease clinics in Slovenia D. Kese, M. Maticic, M. Potocnik Clinical.

Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia C. Carbon, S. Moola,

Surveillance of Legionnaires’ disease in Austria

Clinical Microbiology and Infection

Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain J.-M. Aguado, C. Lumbreras, D.

Vector control: a cornerstone in the malaria elimination campaign

J.P. Donnelly, B.E. De Pauw Clinical Microbiology and Infection

A. Solé, P. Morant, M. Salavert, J. Pemán, P. Morales

Training for the infectious diseases speciality in Norway

Community-acquired pneumonia: the evolving challenge

E. Vermeulen, J. Maertens, P. Meersseman, V. Saegeman, L. Dupont, K

Epidemiology of opportunistic infections in AIDS patients

C. Fabrizio, A. Procopio Clinical Microbiology and Infection

Early invasive fungal infections and colonization in patients with cirrhosis admitted to the intensive care unit E. Theocharidou, B. Agarwal, G. Jeffrey,

Levofloxacin in the treatment of ventilator-associated pneumonia

G. Pappas Clinical Microbiology and Infection

Evaluation of the effect of interleukin-10 on the multiplication of Mycobacterium avium complex in human macrophages and in C57BL/6 mice Hilte F. Geerdes-Fenge,

Evolving epidemiology of invasive Haemophilus infections in the post-vaccination era: results from a long-term population-based study M.R. Berndsen,

Metagenomics and probiotics

Previously unknown species of Aspergillus

A case of pleurisy associated with antibodies to Rickettsia conorii

Voriconazole concentrations and outcome of invasive fungal infections

Update on antifungal resistance in Aspergillus and Candida

Abstracts cont. Clinical Microbiology and Infection

Pandemic lineages of extraintestinal pathogenic Escherichia coli

Identification of risk factors associated with nosocomial infection by rotavirus P4G2, in a neonatal unit of a tertiary-care hospital R. Herruzo, F.

Experience with the Platelia Candida ELISA for the diagnosis of invasive candidosis in neonatal patients S. Oliveri, L. Trovato, P. Betta, M.G. Romeo,

Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci H.L. DuPont, Z.-D. Jiang Clinical Microbiology.

Current experience in treating invasive zygomycosis with posaconazole

Fibronectin concentrations in catheter sepsis

Statin use and clinical outcomes among pneumonia patients

Clinical Microbiology and Infection

Listeriosis: a resurgent foodborne infection

Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis J. Gavaldá, T. Martín, P.

Therapeutic and prophylactic efficacy of aminocandin (IP960) against disseminated candidiasis in mice L.K. Najvar, R. Bocanegra, N.P. Wiederhold, C.

Leishmaniasis in immunosuppressed individuals

K. Kaier, N.T. Mutters, U. Frank Clinical Microbiology and Infection

Z. Erjavec, H. Kluin-Nelemans, P.E. Verweij

The atypical pneumonias: clinical diagnosis and importance

J.J. Keller, M.-C. Tsai, C.-C. Lin, Y.-C. Lin, H.-C. Lin

Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single centre R.R. Laffer, P. Graber, P.E. Ochsner, W. Zimmerli

Abstracts Clinical Microbiology and Infection

Serum ferritin levels in West Nile encephalitis

Modelling during an emergency: the 2009 H1N1 influenza pandemic

J.L. Balcázar Clinical Microbiology and Infection

Impact of antibiotic restrictions: the patient's perspective

Localized Mycobacterium avium complex infection in a patient on HAART

CMI readers' survey Clinical Microbiology and Infection

The future of diagnostic bacteriology

Presentation transcript:

Clinical Microbiology and Infection New dosing strategies for liposomal amphotericin B in high-risk patients Michael Ellis Clinical Microbiology and Infection Volume 14, Pages 55-64 (May 2008) DOI: 10.1111/j.1469-0691.2008.01982.x Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 1 (a) Amphotericin B concentration in lungs after one or four doses of LAB. (b) Fungal burden in lung tissue in mice infected with Aspergillus fumigatus treated for 3 days. Clinical Microbiology and Infection 2008 14, 55-64DOI: (10.1111/j.1469-0691.2008.01982.x) Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 2 (a) Concentrations of amphotericin B in kidney of immunosuppressed mice. (b) Concentrations of amphotericin B in spleen of immunosuppressed mice. Clinical Microbiology and Infection 2008 14, 55-64DOI: (10.1111/j.1469-0691.2008.01982.x) Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 3 (a) Amphotericin B concentration in spleen. (b) Log10 CFU/g kidney at 6 weeks post-treatment. Clinical Microbiology and Infection 2008 14, 55-64DOI: (10.1111/j.1469-0691.2008.01982.x) Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 4 Fungal burden in kidney. Clinical Microbiology and Infection 2008 14, 55-64DOI: (10.1111/j.1469-0691.2008.01982.x) Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 5 High β-D-glucan levels in a patient without invasive fungal infection. Clinical Microbiology and Infection 2008 14, 55-64DOI: (10.1111/j.1469-0691.2008.01982.x) Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 6 Bone marrow concentrations of amphotercin B. Clinical Microbiology and Infection 2008 14, 55-64DOI: (10.1111/j.1469-0691.2008.01982.x) Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions